Does Tenofovir Interact with Fosamprenavir Calcium?

CDI records a unknown classification for Tenofovir and Fosamprenavir Calcium. The stored summary is: 14 ↓15 (↓27 to ↓1) ↓17 (↓27 to ↓6) ↓32 (↓53 to ↓1) 700 mg twice daily plus ritonavir 100 mg twice daily for 14 days (fasted) 14 ↓14 (↓39 to ↑20) ↓17 (↓38 to ↑12) ↓20 (↓45 to ↑17) 700 mg twice daily plus ritonavir 100 mg twice daily for 14 days 12 ↓25 (↓42 to ↓2) ↓25 (↓44 to ↔) ↓33 (↓52 to ↓7) Raltegravir 400 mg twice daily for 14 days 1,400 mg once daily plus ritonavir 100 mg once daily for 14 days (fasted) 13 ↓18 (↓34 to ↔) ↓24 (↓41 to ↔) ↓50 (↓64 to ↓31) 1,400 mg once daily plus ritonavir 100 mg once daily for 14 days 14 ↑27 (↓1 to ↑62) ↑13 (↓7 to ↑38) ↓17 (↓45 to ↑26) Ranitidine 300-mg single dose (administered 1 hour before fosamprenavir) 1,400-mg single dose 30 ↓51 (↓43 to ↓58) ↓30 (↓22 to ↓37) ↔ (↓19 to ↑21) Rifabutin 150 mg every other day for 2 weeks 700 mg twice daily plus ritonavir 100 mg twice daily for 2 weeks 15 ↑36 (↑18 to ↑55) ↑35 (↑17 to ↑56) ↑17 (↓1 to ↑39) Tenofovir 300 mg once daily for 4 to 48 weeks 700 mg twice daily plus ritonavir 100 mg twice daily for 4 to 48 weeks 45 NA NA ↔ Compared with parallel control group. Tenofovir 300 mg once daily for 4 to 48 weeks 1,400 mg once daily plus ritonavir 200 mg once daily for 4 to 48 weeks 60 NA NA ↔ Table 11. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Stored CDI classification

Unknown

Management

Confirm exact products with your pharmacist

Data Source

U.S. FDA via OpenFDA